Ayala Pharmaceuticals, Inc. Common Stock Underwriting AgreementUnderwriting Agreement • March 6th, 2020 • Ayala Pharmaceuticals, Inc. • Biological products, (no disgnostic substances) • New York
This letter agreement is being delivered to you in connection with the proposed underwriting agreement (the “Underwriting Agreement”), among Ayala Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and each of you as representatives (the “Representatives”) of a group of Underwriters named therein, relating to an underwritten public offering of Common Stock, $0.01 par value (the “Common Stock”), of the Company (the “Offering”).
AYALA PHARMACEUTICALS, INC. AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • March 6th, 2020 • Ayala Pharmaceuticals, Inc. • Biological products, (no disgnostic substances) • Delaware
THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”) is made as of December 19, 2018, by and among Ayala Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and each investor listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor, and each of the stockholders listed on Schedule B hereto, each of whom is referred to herein as a “Key Holder”, and any Additional Purchaser (as defined in the Purchase Agreement) that becomes a party to this Agreement in accordance with Section 6.9 hereof.
EMPLOYMENT AGREEMENTEmployment Agreement • March 6th, 2020 • Ayala Pharmaceuticals, Inc. • Biological products, (no disgnostic substances) • Delaware
This EMPLOYMENT AGREEMENT (this “Agreement”), dated as of July 24, 2019 (the “Effective Date”) is by and between Ayala Pharmaceuticals, Inc. (the “Company”), and Gary Gordon (the “Employee”) (individually, each a “Party” and collectively, the “Parties”).
This is a translation into English of the final Hebrew version of the Lease Agreement. In the event of a conflict between the English and Hebrew texts, the Hebrew text shall prevail. Lease Agreement Made and executed in Tel Aviv on the 24th day of...Ayala Pharmaceuticals, Inc. • March 6th, 2020 • Biological products, (no disgnostic substances)
EVALUATION, OPTION AND LICENSE AGREEMENTOption and License Agreement • March 6th, 2020 • Ayala Pharmaceuticals, Inc. • Biological products, (no disgnostic substances) • New York
Certain information marked as [***] has been excluded from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.
ContractLicense Agreement • March 6th, 2020 • Ayala Pharmaceuticals, Inc. • Biological products, (no disgnostic substances) • Delaware
Certain information marked as [***] has been excluded from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.
EMPLOYMENT AGREEMENTEmployment Agreement • March 6th, 2020 • Ayala Pharmaceuticals, Inc. • Biological products, (no disgnostic substances)
This Employment Agreement (this “Agreement”) is entered into effective as of March 15, 2019, by and between Ayala-Oncology Israel Ltd., an Israeli company P.C. No. 51-574869-7 (the “Company”), and Yossi Maimon, Israeli I.D. No. 024821233 (the “Employee”).
EMPLOYMENT AGREEMENTEmployment Agreement • March 6th, 2020 • Ayala Pharmaceuticals, Inc. • Biological products, (no disgnostic substances)
THIS EMPLOYMENT AGREEMENT (the “Agreement”) is effective as of the Effective Date, by and between Ayala Oncology Israel Ltd., a company organized under the laws of the State of Israel, P.C. No. 51-574869-7 (the “Company”) and Employee.
